))
To RNase or Not to RNase: That Is the Question
Manage episode 404603368 series 3381970
Conteúdo fornecido por BMJ Group. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por BMJ Group ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity.
Read the related paper in LSM - https://doi.org/10.1136/lupus-2023-001113
50 episódios
Compartilhar
